Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AbbVie Inc. et al v. Boehringer Ingelheim International GMBH et al
Case Number:
1:17-cv-01065
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 14, 2019
Boehringer Waves White Flag In Humira Patent Battle
Boehringer Ingelheim on Tuesday abandoned its long-shot assault on the patent fortress surrounding AbbVie Inc.'s immunosuppressant Humira, saying it would reluctantly join a long list of biosimilar makers that have agreed to delay competition until 2023.
-
February 25, 2019
Boehringer Must Show How IP 'Thicket' Blocked Humira Rival
Boehringer Ingelheim must hand over its launch plans for a biosimilar version of AbbVie Inc.'s hugely popular immunosuppressant Humira, a Delaware magistrate judge has ruled in a patent infringement case, finding the information is relevant to Boehringer's defense that AbbVie created an illegitimate, anti-competitive "thicket" of duplicative and unoriginal patents.
-
February 08, 2019
AbbVie Must Detail Efforts To Kneecap Humira Biosimilars
AbbVie Inc. has thrown "wrenches into the gears" of high-stakes patent litigation over its hugely popular immunosuppressant Humira, a Delaware magistrate judge said Friday, ordering the drugmaker to swiftly detail any efforts to cripple biosimilar competition.
-
August 31, 2018
Pharma Cases To Watch In 2018's Home Stretch
Drugmakers in the closing months of 2018 may see pivotal rulings on novel efforts to hamstring rival medicines, escalating drama in multidistrict litigation over the opioid epidemic, and opening salvos in False Claims Act and drug-pricing fights at the U.S. Supreme Court. Here, Law360 summarizes key cases to watch.
-
September 13, 2017
AbbVie's Humira Patents Are Noninventive, Boehringer Says
Drugmaker Boehringer Ingelheim International GmbH on Monday shot back at competitor AbbVie Inc.'s suit in Delaware federal court alleging that its proposed biosimilar of the blockbuster immunosuppressant Humira runs afoul of 74 patents, arguing that the company has created a "patent thicket" of noninventive patents to prevent competition.
-
August 02, 2017
Boehringer Biosimilar Flouts 74 Patents, AbbVie Says
Boehringer Ingelheim's proposed biosimilar of the immunosuppressant Humira runs afoul of 74 patents that shield the mega-blockbuster from competition, AbbVie said in a complaint filed Wednesday in Delaware federal court.